IF 4.5 3区 医学 Q2 IMMUNOLOGY
{"title":"An evaluation of the National Influenza Vaccination Program in the Republic of Moldova, 2023–2024","authors":"","doi":"10.1016/j.vaccine.2024.126322","DOIUrl":null,"url":null,"abstract":"<div><p>During the 2023–2024 influenza season, the Republic of Moldova, a lower-middle income country seeking accession into the European Union, independently financed their influenza vaccine supply transitioning from external support from the Partnership for International Vaccine Initiatives, a collaboration conceived in 2015. As part of this transition, a mixed-methods evaluation was conducted from May 2023 – January 2024 to identify current strengths and weaknesses of the influenza vaccination program. A total of 157 interviews were conducted: one with the National Immunization Program (NIP), six with district health officers, 18 at health facilities, 18 with caregivers/parents, 34 with healthcare workers, 43 with adults with chronic diseases, 19 with pregnant women, and 13 vaccine observation sessions; further five expert interviews with an international organization, the insurance company, senior government officials in public health and within the ministry of health, and those involved with COVID-19 were conducted. The Republic of Moldova's NIP has benefited from decades of experience, internal commitments to progress, and contributions from external partners. Despite this progress, the evaluation recognized four areas for improvement. Recommendations from the evaluation assessment included: 1) develop a national strategy for immunization, including the establishment of national goals in consultation with the national immunization technical advisory group (NITAG); 2) expand immunization communications and advocacy initiatives, particularly to adults and pregnant individuals; 3) leverage trusted patient-doctor relationships and encourage vaccination as a healthcare norm with physician specialists; and 4) conduct operations research to better understand vaccine hesitancy in populations such as pregnant individuals. Additional thematic findings emphasized the importance of ensuring timely receipt of vaccine doses into the country no later than September, as medical providers reported difficulty administering doses when vaccines were delivered after September. Our findings outline ways to further strengthen the Republic of Moldova's self-sustained annual influenza vaccination program.</p></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":null,"pages":null},"PeriodicalIF":4.5000,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0264410X24010041","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

摩尔多瓦共和国是一个寻求加入欧盟的中低收入国家,在 2023-2024 年流感季节期间,摩尔多瓦共和国独立资助其流感疫苗供应,从 2015 年构想的 "国际疫苗行动伙伴关系"(Partnership for International Vaccine Initiatives)的外部支持过渡。作为过渡的一部分,在 2023 年 5 月至 2024 年 1 月期间开展了一项混合方法评估,以确定流感疫苗接种计划当前的优势和劣势。共进行了 157 次访谈:1 次与国家免疫计划(NIP)访谈,6 次与地区卫生官员访谈,18 次在卫生机构访谈,18 次与护理人员/家长访谈,34 次与医护人员访谈,43 次与患有慢性病的成年人访谈,19 次与孕妇访谈,以及 13 次疫苗观察会;此外,还与一个国际组织、保险公司、公共卫生和卫生部的高级政府官员以及 COVID-19 的相关人员进行了 5 次专家访谈。摩尔多瓦共和国的国家免疫计划得益于数十年的经验、内部对取得进展的承诺以及 外部合作伙伴的贡献。尽管取得了这些进展,但评估认为有四个方面需要改进。评估提出的建议包括1) 制定国家免疫战略,包括与国家免疫技术咨询组(NITAG)协商制定国家目标;2) 扩大免疫沟通和宣传活动,特别是针对成人和孕妇;3) 利用值得信赖的医患关系,鼓励将疫苗接种作为专科医生的医疗保健规范;以及 4) 开展业务研究,以更好地了解孕妇等人群对疫苗接种的犹豫不决。其他专题调查结果强调了确保在 9 月份之前及时收到疫苗的重要性,因为医疗服务提供者报告称,如果疫苗在 9 月份之后才送达,就很难进行接种。我们的研究结果概述了如何进一步加强摩尔多瓦共和国自我维持的年度流感疫苗接种计划。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
An evaluation of the National Influenza Vaccination Program in the Republic of Moldova, 2023–2024

During the 2023–2024 influenza season, the Republic of Moldova, a lower-middle income country seeking accession into the European Union, independently financed their influenza vaccine supply transitioning from external support from the Partnership for International Vaccine Initiatives, a collaboration conceived in 2015. As part of this transition, a mixed-methods evaluation was conducted from May 2023 – January 2024 to identify current strengths and weaknesses of the influenza vaccination program. A total of 157 interviews were conducted: one with the National Immunization Program (NIP), six with district health officers, 18 at health facilities, 18 with caregivers/parents, 34 with healthcare workers, 43 with adults with chronic diseases, 19 with pregnant women, and 13 vaccine observation sessions; further five expert interviews with an international organization, the insurance company, senior government officials in public health and within the ministry of health, and those involved with COVID-19 were conducted. The Republic of Moldova's NIP has benefited from decades of experience, internal commitments to progress, and contributions from external partners. Despite this progress, the evaluation recognized four areas for improvement. Recommendations from the evaluation assessment included: 1) develop a national strategy for immunization, including the establishment of national goals in consultation with the national immunization technical advisory group (NITAG); 2) expand immunization communications and advocacy initiatives, particularly to adults and pregnant individuals; 3) leverage trusted patient-doctor relationships and encourage vaccination as a healthcare norm with physician specialists; and 4) conduct operations research to better understand vaccine hesitancy in populations such as pregnant individuals. Additional thematic findings emphasized the importance of ensuring timely receipt of vaccine doses into the country no later than September, as medical providers reported difficulty administering doses when vaccines were delivered after September. Our findings outline ways to further strengthen the Republic of Moldova's self-sustained annual influenza vaccination program.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Vaccine
Vaccine 医学-免疫学
CiteScore
8.70
自引率
5.50%
发文量
992
审稿时长
131 days
期刊介绍: Vaccine is unique in publishing the highest quality science across all disciplines relevant to the field of vaccinology - all original article submissions across basic and clinical research, vaccine manufacturing, history, public policy, behavioral science and ethics, social sciences, safety, and many other related areas are welcomed. The submission categories as given in the Guide for Authors indicate where we receive the most papers. Papers outside these major areas are also welcome and authors are encouraged to contact us with specific questions.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信